Mini-Lecture Series: 2022 ID Week Conference Summary

Dr. Jehan Budak's ID Week 2022 update focuses on key results from the BEe-HIVe study (B-Enhancement of HBV Vaccination in persons living with HIV) and oral abstracts on real world outcomes from use of long acting injectable cabotegravir-rilpivirine.
0:00 Introduction
0:39 BEe-HIVe Preliminlary Results and Background
1:45 BEe-HIVe Study Design
2:43 BEe-HIVe Arm B Methods
3:55 BEe-HIVe Arm B Seroprotection Rate by Study Week
4:44 BEe-HIVe Arm B Adverse Effects
5:09 BEe-HIVe Arm B Preliminary Results Summary
6:12 Outcomes with LAI CAB-RPV
6:42 Effectiveness of LAI CAB-RPV in OPERA Cohort
7:47 Low Level HBViremia after Switch to CAB-RPV in HBcAb Positivity
9:01 CARISEL: Implementation of LAI CAB-RPV in the EU
9:48 Conclusions